Philipp Gild

Philipp Gild

Auto-generated profile, based on publicly available information

Philipp Gild

Department of Urology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Asian Journal of Urology
Verified
Journal Article
Open access
PGPhilipp Gild
Philipp Gild
LKLuis A. Kluth
Luis A. Kluth
MVMalte W. Vetterlein
Malte W. Vetterlein
OEOliver Engel
Oliver Engel
FCFelix K.H. Chun
Felix K.H. Chun
MFMargit Fisch
Margit Fisch
Iatrogenic ureteral injuries and strictures are relatively common complication of pelvic surgery and radiation treatment. Left untreated they are associated with severe short- and long-term complications such as urinoma, septic state, renal failure, and loss of a renal unit. Treatment depends on timing of diagnosis, as well as extent of injury, and ranges from simple endoscopic management to complex surgical reconstruction under usage of pedicled grafts. While recent advances in ureteral tissue engineering are promising the topic is still underreported. Historically a domain of open surgery, laparoscopic and robotic-assisted approaches have proven their feasibility in small case series, and are increasingly being utilized as means of reconstructive surgery. This review aims to give an outline of incidence and treatment of ureteral injuries and strictures in light of the latest advances.

Verified
Journal Article
Open access
PDF file
GAGunhild Von Amsberg
Gunhild Von Amsberg
MZMirjam Zilles
Mirjam Zilles
WMWael Mansour
Wael Mansour
PGPhilipp Gild
Philipp Gild
WAWinfried Alsdorf
Winfried Alsdorf
CBCarsten Bokemeyer
Carsten Bokemeyer
Significant progress has been achieved in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, results in patients with aggressive variant prostate cancer (AVPC) have been disappointing. Here, we report retrospectively collected data from intensively pretreated AVPC patients (n = 17; 88.2% visceral metastases; 82% elevation of neuroendocrine markers) treated with salvage chemotherapy consisting of cisplatin, ifosfamide, and paclitaxel (TIP). At the interim analysis, 60% of patients showed radiographic response or stable disease (PFS = 2.5 months; OS = 6 months). In men who responded to chemotherapy, an OS > 15 months was observed. Preclinical analyses confirmed the high activity of the TIP regimen, especially in docetaxel-resistant prostate cancer cells. This effect was primarily mediated by increased cisplatin sensitivity in the emergence of taxane resistance. Proteomic and functional analyses identified a lower DNA repair capacity and cell cycle machinery deficiency to be causative. In contrast, paclitaxel showed inconsistent effects, partially antagonizing cisplatin and ifosfamide in some AVPC models. Consequently, paclitaxel has been excluded from the TIP combination for future patients. In summary, we report for the first time the promising efficacy of TIP as salvage therapy in AVPC. Our preclinical data indicate a pivotal role for cisplatin in overcoming docetaxel resistance.

16 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLSimon Hannes Friedrich LESCHIK
Simon Hannes Friedrich LESCHIK
RSRobert grosse Siemer
Robert grosse Siemer
FRFriedrich-Carl von Rundstedt
Friedrich-Carl von Rundstedt
PGPhilipp Gild
Philipp Gild
CMChristian Paul Meyer
Christian Paul Meyer
TFTobias Franiel
Tobias Franiel
Background: This retrospective matched-pair analysis compared functional outcomes and complications of prostate artery embolization (PAE) using 250 µm microparticles and holmium laser enucleation of the prostate (HoLEP) in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Methods: A total of 69 PAE patients were matched 1:1 to 69 HoLEP patients using propensity scores based on age, prostate volume (PV), and IPSS. Follow-up was standardized at six months for the PAE cohort, while HoLEP outcomes were assessed cross-sectionally (median 52.9 months). All comparisons were therefore interpreted as cross-sectional analyses rather than time-matched outcomes. Secondary endpoints were complications according to the Clavien–Dindo Classification. Results: At baseline, there were no significant differences between PAE and HoLEP regarding IPSS, QoL, or Qmax. Both interventions led to significant within-group improvements in IPSS, QoL, and Qmax (p < 0.001). Between-group comparisons demonstrated significantly greater improvement in IPSS, Qmax, and QoL following HoLEP (all p < 0.05). Erectile function remained stable after PAE and showed a non-significant decrease after HoLEP. Severe complications (Clavien–Dindo ≥ Grade III) were not observed after PAE. These findings should be interpreted considering the study’s main limitations, including the small cohort size, its retrospective matched-pair design, and variability in surgeons’ HoLEP experience. Conclusions: PAE with 250 µm microparticles and HoLEP are both effective and safe procedures. While PAE compared to HoLEP is less effective regarding functional outcome, it showed no difference in QoL improvement and is associated with no greater grade II complications.